Initiation of heroin and prescription opioid pain relievers by birth cohort

American Journal of Public Health

Volumn 106, Issue 2, 2016, Pages 298-300

  Novak, Scott P ^a   Bluthenthal, Ricky ^a   Wenger, Lynn ^b   Chu, Daniel ^a   Kral, Alex H ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; CALIFORNIA; COHORT ANALYSIS; HUMAN; MIDDLE AGED; ONSET AGE; PAIN; PRESCRIPTION DRUG MISUSE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANALGESICS, OPIOID; CALIFORNIA; COHORT STUDIES; HEROIN; HUMANS; MIDDLE AGED; PAIN; PRESCRIPTION DRUG MISUSE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84955577851     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302972     Document Type: Article

References (13)

1. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008.MMWRMorb Mortal Wkly Rep. 2011; 60(43):1487-1492.
2. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12): 1274-1282.
3. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559-574.
4. Bluthenthal RN, Watters JK. Multimethod research from targeted sampling to HIV risk environments. NIDA Res Monogr. 1995;157:212-230.
5. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Probl. 1989;36(4): 416-430.
6. Substance Abuse and Mental Health Services Administration. Results From the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD; 2013. NSDUH series H-46, HHS publication SMA 13-4795.
7. Kilmer B, Everingham S, Caulkins J, et al. What America's Users Spend on Illegal Drugs: 2000-2010. Santa Monica, CA: Rand Corporation; 2014.
8. Van Zee A. The promotion and marketing of Oxy-Contin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.
9. Lanser P, Gesell S. Pain management: The fifth vital sign. Healthc Benchmarks. 2001;8(6):68-70, 62.
10. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821-826.
11. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9-17.
12. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351-358.
13. Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA. 2011;306(20):2258-2259.